metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Optimizing prostate cancer screening; prospective randomized controlled study of...
Journal Information
Vol. 38. Issue 4.
Pages 217-223 (May 2014)
Share
Share
Download PDF
More article options
Visits
587
Vol. 38. Issue 4.
Pages 217-223 (May 2014)
Original article
Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program
Optimización de un programa de cribado oportunista de cáncer de próstata; ensayo aleatorizado prospectivo del papel del PSA y del PCA3 en uso secuencial
Visits
587
J. Rubio-Brionesa,
Corresponding author
jrubio@fivo.org

Corresponding author.
, J. Casanovaa, R. Dumonta, L. Rubiob, A. Fernandez-Serrab, I. Casanova-Salasb, J. Domínguez-Escriga, M. Ramírez-Backhausa, A. Colladoa, A. Gómez-Ferrera, I. Iborraa, J.L. Monrósa, J.V. Ricósa, E. Solsonaa, D. Salasc, F. Martínezd, J.A. Lopez-Guerrerob
a Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain
b Laboratorio de Biología Molecular, Fundación Instituto Valenciano de Oncología, Valencia, Spain
c Departamento de Salud Pública, Consellería de Sanidad, Generalitat Valenciana, Valencia, Spain
d Departamento de Bioestadística, Universidad de Valencia, Valencia, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (2)
Table 1. Results of the initial biopsy and follow-up biopsies and Gleason score according to PCA3 branch.
Table 2. Statistics for various PCA3 cutoff points.
Show moreShow less
Abstract
Objectives

To reduce unnecessary biopsies (Bx) in an opportunistic screening programme of prostate cancer.

Material and methods

We performed a prospective evaluation of PCA3 as a second-line biomarker in an opportunistic screening for prostate cancer (PCa). From September 2010 until September 2012, 2,366 men, aged 40–74 years and with >10 years life expectancy, were initially screened with PSA/digital rectal examination (DRE). Men with previous Bx or with recent urine infections were excluded. Men with abnormal DRE and/or PSA>3ng/ml were submitted for PCA3. All men with PCA335 underwent an initial biopsy (IBx) —12cores—. Men with PCA3<35 were randomized 1:1 to either IBx or observation. Re-biopsy (16–18 cores) criteria were PSA increase>.5ng/ml at 4-6months or PSAv>.75ng/ml/year.

Results

With a median follow-up (FU) of 10.1months, PCA3 was performed in 321/2366 men (13.57%), 289 at first visit and 32 during FU. All 110 PCA3+ men (34.3%) were biopsied and PCa was identified in 43 men in IBx (39.1%). In the randomized arm, 110 were observed and 101 underwent biopsy, finding 12 PCa (11.9%), showing a statistically significant reduction of PCa detection rate in this cohort (p<.001). Global PCa detection rates were 40.9% and 9.5% for the PCA3+ and PCA3− branches, respectively (p<.001). Area under the curve for PSA and PCA3 were .601 and .74, respectively. This is an ongoing prospective study limited by its short follow-up period and still limited enrolment.

Conclusions

PCA3 as a second-line biomarker within an opportunistic dual screening protocol can potentially avoid 65.7% and 50.1% biopsies at first round and at median FU of 10.1months, respectively, just missing around 3.2% of high grade PCa.

Keywords:
Prostate cancer
Screening
PCA3
Prostate biopsy
Resumen
Objetivos

Reducir el número de biopsias (Bx) innecesarias en un programa de cribado oportunista en cáncer de próstata (CaP).

Material y métodos

Estudio prospectivo y aleatorizado evaluando el PCA3 como biomarcador de segunda línea. De septiembre de 2010 a septiembre de 2012 2.366 hombres con edad en rango 40–74 años, y más de 10 años de expectativa de vida, fueron estudiados mediante PSA y tacto rectal (TR), excluyendo los biopsiados previamente o con infección urinaria reciente. Ante un TR sospechoso y/o PSA>3ng/ml se les realizó un PCA3. A todos aquellos con PCA335 se les realizó una Bx inicial (IBx) —12 cilindros—. Con PCA3<35 fueron aleatorizados 1:1 a IBx u observación. Los criterios de rebiopsia (16–18 cilindros) durante el seguimiento fueron un incremento de PSA>0,5ng/ml a 6meses o PSAv>0,75ng/ml/año.

Resultados

Con un seguimiento medio de 10,1 meses se testó el PCA3 en 321/2.366 hombres (13,57%), 289 en la primera visita y 32 durante el seguimiento. Entre los 110 hombres con PCA3+ (34,3%) se identificó CaP en 43 en IBx (39,1%). En el brazo aleatorizado 110 se observaron y 101 se biopsiaron, encontrando 12 CaP (11,9%), mostrando un reducción en la detección de CaP estadísticamente significativa en esta cohorte (p<0,001). Las tasas de detección global de CaP fueron de 40,9 y 9,5% para las ramas PCA3+ y PCA3− respectivamente (p<0,001). AUC para PSA y PCA3 fueron 0,601 y 0,74. Este es un protocolo abierto en este momento, limitado por su seguimiento insuficiente.

Conclusiones

El PCA3 como biomarcador de segunda línea en un programa de cribado oportunista podría potencialmente evitar un 65,7% de IBx y 50,1% a 10 meses de seguimiento, dejando de diagnosticar 3,2% de CaP de alto grado.

Palabras clave:
Cáncer de próstata
Cribado
PCA3
Biopsia prostática

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos